{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:53:23Z","timestamp":1794099203048,"version":"4.8.0"},"reference-count":51,"publisher":"Baishideng Publishing Group Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4254\/wjh.v7.i9.1251","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T07:06:56Z","timestamp":1432019216000},"page":"1251","source":"Crossref","is-referenced-by-count":52,"title":["Valproic acid and nonalcoholic fatty liver disease: A possible association?"],"prefix":"10.4254","volume":"7","author":[{"given":"Edoardo","family":"Farinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.01.021"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20842"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/phe.09.21"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-13-40"},{"key":"ref7","unstructured":"Chopra S. Patient information. Nonalcoholic steatohepatitis (NASH) (Beyond the basics). [Up date 2013]. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.uptodate.com\/contents\/nonalcoholic-fatty-liver-disease-nafld-including-nonalcoholic-steatohepatitis-nash-beyond-the-basics\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.uptodate.com\/contents\/nonalcoholic-fatty-liver-disease-nafld-including-nonalcoholic-steatohepatitis-nash-beyond-the-basics<\/ext-link>."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.6017"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.192401"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088005"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2010.10.002"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.003"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200608020-00004"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1192\/apt.10.5.389"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00004"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.2.285"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2013.06.012"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.6.673"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840020513"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840020622"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Olson MJ, Handler JA, Thurman RG. Mechanism of zone-specific hepatic steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the liver lobule. Mol Pharmacol 1986;30:520-525.","DOI":"10.1016\/S0026-895X(25)10413-6"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6291.577"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00800.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000113927"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.09.007"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-268.","DOI":"10.1177\/088307380201700405"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1559-4572.2008.00030.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1030"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187074.27586.d1"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200101501"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.1.230"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2007.04.001"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.947"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807307096"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.31501.x"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.06.001"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(03)00091-3"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Shi Y, Kanaani J, Menard-Rose V, Ma YH, Chang PY, Hanahan D, Tobin A, Grodsky G, Baekkeskov S. Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab 2000;279:E684-E694.","DOI":"10.1152\/ajpendo.2000.279.3.E684"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1159\/000098053"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;52:1-8.","DOI":"10.2337\/diabetes.52.1.1"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(80)90042-8"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.1.7"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.22565"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20555"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02206.x"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20074"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.04.004"},{"key":"ref48","unstructured":"Ortiz-S&aacute;enz de Santa Mar&iacute;a R, Santiago-Fern&aacute;ndez C, Cano-Del Pozo M, P&eacute;rez-Gil O, Soto-Alvarez MI, Barriuso-P&eacute;rez E, Moche-Loeri JA. [Treatment with valproate and hepatic steatosis]. Rev Neurol 2005;41:766-767."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-009-0927-y"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.12.012"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Saleh DA, Ismail MA, Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci 2012;15:68-77.","DOI":"10.3923\/pjbs.2012.68.77"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v7\/i9\/1251.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T01:04:46Z","timestamp":1748394286000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v7\/i9\/1251.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v7.i9.1251","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}